News and Events

Dr. Karina Eterovic joins Viracor as the Director of Research & Development for Oncology Diagnostics for Eurofins U.S. Clinical Diagnostics group

Transplant Genomics, Inc. receives notice that the Molecular Diagnostics Services (MolDX) Program developed by Palmetto GBA has set TruGraf reimbursement.

Transplant Genomics and Viracor's innovative TruGraf ® Blood Gene Expression Test qualifies for Medicare coverage effective November 25, 2019. 

Eurofins Viracor, Inc. (“Viracor”) became aware today that CareDx has filed suit in the United States District Court for District of Delaware, alleging infringement of U.S. Patent No. 8,703,652 by three of Viracor’s tests:  Viracor TRAC™ Kidney dd-cfDNA, Viracor TRAC™ Heart dd-cfDNA and Viracor TRAC™ Lung dd-cfDNA.

Eurofins Scientific (EUFI.PA), announces that it has successfully closed the acquisition of Transplant Genomics Inc. (“TGI”), a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive serial monitoring guided by genomics. TGI’s innovative non-invasive tests for the management of patients with silent inflammation and rejection following kidney transplants will strengthen and complement Eurofins’ industry leading global Transplant Diagnostics offerings.

Baloxavir Resistance Testing was developed for the detection of I38T/M/F mutations in H3N2 and 2009 H1N1 strains of Influenza A (flu A) to aid in the evaluation of resistance to the recent FDA approved drug.